STOCK TITAN

Reviva Pharmaceuticals Holdings Inc. - RVPH STOCK NEWS

Welcome to our dedicated news page for Reviva Pharmaceuticals Holdings (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceuticals Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Reviva Pharmaceuticals Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Reviva Pharmaceuticals Holdings's position in the market.

Rhea-AI Summary
Reviva Pharmaceuticals gains FDA alignment for brilaroxazine clinical trials in schizophrenia, with potential NDA support. Topline data from long-term safety study expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported successful results from the RECOVER-1 Phase 3 trial for brilaroxazine in schizophrenia, with plans to initiate the RECOVER-2 trial in 2024. The company expects to submit a New Drug Application (NDA) in 2025. Financially, the net loss for 2023 was $39.3 million, compared to $28.3 million in 2022, with cash and equivalents at $23.4 million in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announces Dr. Laxminarayan Bhat's presentation at the 2024 SIRS Annual Meeting in Italy regarding Brilaroxazine Phase 3 Recover Trial in Acute Schizophrenia, showcasing efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences clinical trial
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that their CEO will present a poster at the ASCPT 2024 Annual Meeting on Brilaroxazine Efficacy in the Phase 3 RECOVER Trial for Acute Schizophrenia. The presentation will focus on addressing unmet medical needs in CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.97%
Tags
conferences clinical trial
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that their CEO will participate in a Fireside Chat at the UBS Virtual CNS Day on March 18, 2024, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
conferences
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced that its Founder, President, and CEO will present at the 36th Annual ROTH Conference to discuss the company's late-stage pharmaceutical developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that its CEO will present at the 2024 BIO CEO & Investor Conference in New York, focusing on therapies for CNS, inflammatory, and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will host a virtual event on February 15, 2024, featuring key opinion leaders discussing the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia. The event will focus on the positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
conferences clinical trial
-
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced the participation of its CEO in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host virtual one-on-one meetings with investors. The webcasted fireside chat will take place on February 1, 2024, and will be available for replay. Management will be participating in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announces CEO presentation at Webull LIVE! Virtual Healthcare Investment Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
conferences
Reviva Pharmaceuticals Holdings Inc.

Nasdaq:RVPH

RVPH Rankings

RVPH Stock Data

103.02M
17.14M
17.77%
18.78%
3.79%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cupertino

About RVPH

reviva pharmaceuticals is a pharmaceuticals company located in 5941 optical ct, san jose, california, united states.